A Phase II Evaluation of Mifepristone in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma
- Determine the antitumor activity of mifepristone in patients with recurrent or
persistent ovarian epithelial, primary peritoneal, or fallopian tube carcinoma.
- Determine the toxicity of this drug in these patients.
- Determine the duration of progression-free survival and overall survival of patients
treated with this drug.
- Determine the potential impact of platinum sensitivity, initial performance status, and
age on prognosis in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral mifepristone once daily on days 1-28. Treatment repeats every 4 weeks
in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed periodically for 5 years.
PROJECTED ACCRUAL: A total of 52 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Proportion of patients with progression-free survival for at least 6 months
Thomas F. Rocereto, MD
Cancer Institute of New Jersey at Cooper - Voorhees
United States: Federal Government
|George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus||New Britain, Connecticut 06050|
|Hinsdale Hematology Oncology Associates||Hinsdale, Illinois 60521|
|Case Comprehensive Cancer Center||Cleveland, Ohio 44106-5065|
|Marshfield Clinic - Marshfield Center||Marshfield, Wisconsin 54449|
|Kaiser Permanente Medical Center - Los Angeles||Los Angeles, California 90027|
|University of Texas Medical Branch||Galveston, Texas 77555-1329|
|Hulston Cancer Center at Cox Medical Center South||Springfield, Missouri 65807|
|Lake/University Ireland Cancer Center||Mentor, Ohio 44060|
|Women and Infants Hospital of Rhode Island||Providence, Rhode Island 02905|
|Riverside Methodist Hospital Cancer Care||Columbus, Ohio 43214|
|Oklahoma University Cancer Institute||Oklahoma City, Oklahoma 73104|
|Methodist Estabrook Cancer Center||Omaha, Nebraska 68114-4199|
|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center||Hartford, Connecticut 06105|
|Maine Medical Center - Bramhall Campus||Portland, Maine 04102|
|Rosenfeld Cancer Center at Abington Memorial Hospital||Abington, Pennsylvania 19001|
|Cancer Institute of New Jersey at Cooper - Voorhees||Voorhees, New Jersey 08043|
|Bryn Mawr Hospital||Bryn Mawr, Pennsylvania 19010|
|Lankenau Cancer Center at Lankenau Hospital||Wynnewood, Pennsylvania 19096|
|Regional Cancer Center at Singing River Hospital||Pascagoula, Mississippi 39581|
|Woman's Hospital||Baton Rouge, Louisiana 70815|
|Freeman Cancer Institute at Freeman Health System||Joplin, Missouri 64803-2644|
|Cancer Center of Paoli Memorial Hospital||Paoli, Pennsylvania 19301-1792|